Additive Pharmacological Interaction Between Sirtuin Inhibitor Cambinol and Paclitaxel in MCF7 Luminal and MDA-MB-231 Triple-negative Breast Cancer Cells

Overview

Journal Pharmacol Rep

Specialty Pharmacology

Date 2022 Jul 28

PMID 35900723

Authors

Anna Wawruszak

Estera Okon

Ilona Telejko

Arkadiusz Czerwonka

Jarogniew Luszczki

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer (BC) is the most common malignancy and the leading cause of cancer-related death in women worldwide. Sirtuin inhibitors (SIRTi), belonging to the histone deacetylase inhibitors group (HDIs), are potent epigenetic drugs that have been investigated for therapeutic use in different clinical disorders, including hematological malignancies and solid tumors.

Methods: The influence of cambinol (CAM; SIRTi) used individually or in combination with standard chemotherapeutic paclitaxel (PAX) on viability (MTT assay), proliferation (BrdU assay), induction of apoptosis and cell cycle arrest (FACS analysis) was determined in MCF7 luminal and MDA-MB-231 triple-negative breast cancer (TNBC) cells. The types of pharmacological drug-drug interaction between CAM and PAX were determined by an exact and rigorous pharmacodynamic method-an isobolography, to determine the presence of synergism, addition or antagonism between analyzed drugs using a variety of fixed-dose ratios.

Results: The combination of CAM and PAX at a fixed ratio of 1:1 exerted additive interaction in the viability of MCF7 and MDA-MB-231 BC cells. Both active agents used separately reduced viability and proliferation of BC cells as well as induced apoptosis and cell cycle arrest. These effects were much more evident in MCF7 than in MDA-MB-231 BC cells. Additionally, CAM combined with PAX increased anti-cancer activity compared to PAX used alone.

Conclusion: CAM might be considered a potential therapeutic agent individually or in combined therapy with PAX against luminal or TNBC.

Citing Articles

Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.

Wawruszak A, Luszczki J, Bartuzi D, Kalafut J, Okon E, Czerwonka A J Enzyme Inhib Med Chem. 2025; 40(1):2458554.

PMID: 39935420 PMC: 11823383. DOI: 10.1080/14756366.2025.2458554.

Targeting sirtuins for cancer therapy: epigenetics modifications and beyond.

Shen H, Qi X, Hu Y, Wang Y, Zhang J, Liu Z Theranostics. 2024; 14(17):6726-6767.

PMID: 39479446 PMC: 11519805. DOI: 10.7150/thno.100667.

References

Grabovsky Y, Tallarida R . Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther. 2004; 310(3):981-6. DOI: 10.1124/jpet.104.067264. View

Portmann S, Fahrner R, Lechleiter A, Keogh A, Overney S, Laemmle A . Antitumor effect of SIRT1 inhibition in human HCC tumor models in vitro and in vivo. Mol Cancer Ther. 2013; 12(4):499-508. DOI: 10.1158/1535-7163.MCT-12-0700. View

Yang Y, Mao J, Tan X . Research progress on the source, production, and anti-cancer mechanisms of paclitaxel. Chin J Nat Med. 2020; 18(12):890-897. DOI: 10.1016/S1875-5364(20)60032-2. View

Wawruszak A, Luszczki J, Czerwonka A, Okon E, Stepulak A . Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer Cells. Cells. 2022; 11(7). PMC: 8998062. DOI: 10.3390/cells11071211. View

Giordano S, Freedman R, Somerfield M . Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update. J Clin Oncol. 2021; 40(3):307-309. DOI: 10.1200/JCO.21.02677. View

Liang Z, Yang Y, Wang H, Yi W, Yan X, Yan J . Inhibition of SIRT1 signaling sensitizes the antitumor activity of silybin against human lung adenocarcinoma cells in vitro and in vivo. Mol Cancer Ther. 2014; 13(7):1860-72. DOI: 10.1158/1535-7163.MCT-13-0942. View

Holloway K, Barbieri A, Malyarchuk S, Saxena M, Nedeljkovic-Kurepa A, Cameron Mehl M . SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Mol Endocrinol. 2013; 27(3):480-90. PMC: 3589668. DOI: 10.1210/me.2012-1347. View

Tallarida R . Interactions between drugs and occupied receptors. Pharmacol Ther. 2006; 113(1):197-209. PMC: 2045509. DOI: 10.1016/j.pharmthera.2006.08.002. View

Sinha S, Sharma S, Vora J, Shrivastava N . Emerging role of sirtuins in breast cancer metastasis and multidrug resistance: Implication for novel therapeutic strategies targeting sirtuins. Pharmacol Res. 2020; 158:104880. DOI: 10.1016/j.phrs.2020.104880. View

10.

Lautz T, Naiditch J, Clark S, Chu F, Madonna M . Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma. J Pediatr Surg. 2012; 47(6):1267-71. DOI: 10.1016/j.jpedsurg.2012.03.039. View

11.

Halasa M, Luszczki J, Dmoszynska-Graniczka M, Baran M, Okon E, Stepulak A . Antagonistic Interaction between Histone Deacetylase Inhibitor: Cambinol and Cisplatin-An Isobolographic Analysis in Breast Cancer In Vitro Models. Int J Mol Sci. 2021; 22(16). PMC: 8395248. DOI: 10.3390/ijms22168573. View

12.

Dan V, Raveendran R, Baby S . Resistance to Intervention: Paclitaxel in Breast Cancer. Mini Rev Med Chem. 2020; 21(10):1237-1268. DOI: 10.2174/1389557520999201214234421. View

13.

Chowdhury S, Sripathy S, Webster A, Park A, Lao U, Hsu J . Discovery of Selective SIRT2 Inhibitors as Therapeutic Agents in B-Cell Lymphoma and Other Malignancies. Molecules. 2020; 25(3). PMC: 7036909. DOI: 10.3390/molecules25030455. View

14.

Huang M, Zhang J, Yan C, Li X, Zhang J, Ling R . Small molecule HDAC inhibitors: Promising agents for breast cancer treatment. Bioorg Chem. 2019; 91:103184. DOI: 10.1016/j.bioorg.2019.103184. View

15.

Tallarida R . An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther. 2006; 319(1):1-7. DOI: 10.1124/jpet.106.104117. View

16.

Ceballos M, Angel A, Delprato C, Livore V, Ferretti A, Lucci A . Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells. Eur J Pharmacol. 2020; 892:173736. DOI: 10.1016/j.ejphar.2020.173736. View

17.

Cea M, Soncini D, Fruscione F, Raffaghello L, Garuti A, Emionite L . Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One. 2011; 6(7):e22739. PMC: 3144930. DOI: 10.1371/journal.pone.0022739. View

18.

Tallarida R . Drug Combinations: Tests and Analysis with Isoboles. Curr Protoc Pharmacol. 2016; 72:9.19.1-9.19.19. PMC: 4839184. DOI: 10.1002/0471141755.ph0919s72. View

19.

Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A . Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. Int J Mol Sci. 2022; 23(3). PMC: 8836182. DOI: 10.3390/ijms23031665. View

20.

Ceballos M, Decandido G, Quiroga A, Comanzo C, Livore V, Lorenzetti F . Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines. Toxicol Lett. 2018; 289:63-74. DOI: 10.1016/j.toxlet.2018.03.011. View